Skip to main content

Latest stock market podcasts

From the helm: Cyclopharm’s (ASX:CYC) MD & CEO, James McBrayer

Bell Direct
February 5, 2021

In this instalment of our From the helm series, Bell Direct’s Jessica Amir speaks to Cyclopharm’s (ASX:CYC) MD & CEO, James McBrayer.

Cyclopharm is a little known Aussie company. Its medical technology is used in 60 countries around the world to help doctors identify lung capacity, as well as find potential blood clots. With earnings mostly coming from Europe, CYC’s US journey gathers momentum with USFDA approval looming. The US is home to the world’s largest nuclear medicine market.

In this video James discusses:

  • (0:31) What CYC does & its “imminent” entry into the US
  • (1:11) Key catalysts to drive share price growth – (1:47) Commercialising the product in the US
  • (2:46) CYC’s product being endorsed to help fight COVID-19 in the US – (3:31) How the company has reduced its risks
  • (4:56) After a 110% rise in share price last year, what can investors expect for the year ahead?

Weekly Wrap 6 December

Bell Direct
December 6, 2024

Morning Bell 6 December

Bell Direct
December 6, 2024

Morning Bell 5 December

Bell Direct
December 5, 2024

Morning Bell 4 December

Sophia Mavridis
December 4, 2024

Morning Bell 3 December

Sophia Mavridis
December 3, 2024

Morning Bell 2 December

Bell Direct
December 2, 2024

Weekly Wrap 29 November

Bell Direct
November 29, 2024

Morning Bell 28 November

Bell Direct
November 28, 2024

Morning Bell 27 November

Bell Direct
November 27, 2024

Bell Direct
November 26, 2024

Morning Bell 25 November

Bell Direct
November 25, 2024

Morning Bell 21 November

Bell Direct
November 21, 2024